Catalysed by the pandemic, the overall virtual clinical trials market has grown rapidly and is now valued at US$7.8 billion with a projected growth of 14% per annum . Cambridge Cognition is an active player in the central nervous system (CNS) market, supplying digital solutions to assess brain health. Now, in a major strategic move that will accelerate the company’s growth, Cambridge Cognition has entered an agreement to acquire eClinicalHealth (eCH); a full-service digital technology provider that is working on virtual clinical trials for three of the world’s top ten largest pharmaceutical companies. By integrating eCH’s patient-centric Clinpal platform, Cambridge Cognition will be able to offer clients a fully integrated solution covering all trial modules – from recruitment to clinical reporting.
Virtual clinical trials are increasingly regarded as the future of drug development because they provide the technology to decentralise testing and therefore an opportunity to improve recruitment, retention, trial diversity, trial delays and costs . Recognising this value, a recent survey found that 89% of pharmaceutical companies are currently deploying some form of virtual technology in their trials . Many CNS disorders, such as depression and Alzheimer’s disease, are particularly suited to virtual trials as at home daily measurements can offer richer information on the progress of the condition. Consequently, over the last two years, there have been more virtual trials for CNS disorders than any other therapeutic area .